Literature DB >> 28334868

Pulmonary metastasis from giant cell tumor of bone: clinical outcome prior to the introduction of molecular target therapy.

Munehisa Kito1, Seiichi Matusmoto1, Keisuke Ae1, Taisuke Tanizawa1, Tabu Gokita1, Hiroshi Kobayashi1, Keiko Hayakawa1, Yuki Funauchi1.   

Abstract

OBJECTIVE: We analyzed the risk factors for pulmonary metastasis from giant cell tumor of bone and aimed to discuss their therapeutic strategy and appropriate follow-up period.
METHODS: We analyzed 141 patients of giant cell tumor of bone. The variables analyzed included age, gender, primary site, Campanacci grading, surgical treatment on the primary lesion, radiotherapy and local recurrence.
RESULTS: Pulmonary metastasis occurred in 12 patients. The risk factors were young age, Campanacci Grade III and local recurrence. Median time from initial surgery to metastasis was 1.3 years (0-3.1 years). Among them, eight patients experienced local recurrence of the primary tumor, and the median time from initial surgery to local recurrence was 0.8 years (0.3-2.9 years). Among seven patients who underwent wide resection, three patients showed local recurrence of the soft tissue. Nine patients underwent metastasectomy for pulmonary metastases. Of three patients who did not undergo metastasectomy, one patient died of uncontrollable metastases, and two patients showed no changes in their metastatic lesions.
CONCLUSIONS: Although we found a correlation between local recurrence and pulmonary metastasis, we were still unable to prevent local or metastatic recurrence by wide resection. Local recurrence and metastasis have been found within ~3 years after initial surgery, and routine image examinations of the primary site and chest after initial surgical treatment should be considered for at least 3 years postoperatively.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  follow-up period; giant cell tumor of bone; local recurrence; metastasectomy; pulmonary metastasis

Mesh:

Year:  2017        PMID: 28334868     DOI: 10.1093/jjco/hyx033

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.

Authors:  Shinji Tsukamoto; Andreas F Mavrogenis; Giulio Leone; Alberto Righi; Manabu Akahane; Piergiuseppe Tanzi; Akira Kido; Kanya Honoki; Yasuhito Tanaka; Davide Maria Donati; Costantino Errani
Journal:  Int Orthop       Date:  2018-08-11       Impact factor: 3.075

2.  Development and validation of a prognostic index to predict pulmonary metastasis of giant cell tumor of bone.

Authors:  Bo Wang; Wei Chen; Xianbiao Xie; Jian Tu; Gang Huang; Changye Zou; Junqiang Yin; Lili Wen; Jingnan Shen
Journal:  Oncotarget       Date:  2017-11-08

3.  Giant cell tumor of bone: Unusual features of a rare tumor.

Authors:  Ziyad M Mohaidat; Hisham Z Al-Jamal; Audai M Bany-Khalaf; Ahmad M Radaideh; Ziad A Audat
Journal:  Rare Tumors       Date:  2019-09-25

4.  Outcome of lung metastases due to bone giant cell tumor initially managed with observation.

Authors:  Shinji Tsukamoto; Giovanni Ciani; Andreas F Mavrogenis; Cristina Ferrari; Manabu Akahane; Yasuhito Tanaka; Michele Rocca; Alessandra Longhi; Costantino Errani
Journal:  J Orthop Surg Res       Date:  2020-11-07       Impact factor: 2.359

5.  Prognostic Factors for Survival in Patients with Malignant Giant Cell Tumor of Bone: A Risk Nomogram Analysis Based on the Population.

Authors:  Xiaolong Zhu; Runzhi Huang; Peng Hu; Penghui Yan; Suna Zhai; Jie Zhang; Junwei Zhuang; Huabin Yin; Tong Meng; Daoke Yang; Zongqiang Huang
Journal:  Med Sci Monit       Date:  2021-02-17

Review 6.  Metastatic giant cell tumour of bone: a narrative review of management options and approaches.

Authors:  Ruiwen Xu; Peter F M Choong
Journal:  ANZ J Surg       Date:  2022-02-10       Impact factor: 2.025

7.  Risk factors and oncological outcomes of pulmonary metastasis in patients with giant cell tumor of bone.

Authors:  Walid Atef Ebeid; Ismail Tawfeek Badr; Mohamed Kamal Mesregah; Bahaa Zakarya Hasan
Journal:  J Clin Orthop Trauma       Date:  2021-07-09

8.  Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.

Authors:  Josef Yayan
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.